Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial;Vergleich von Dapagliflozin und Glipizid als Add-on-Therapie bei Typ-2-Diabetikern mit unzureichender Blutzuckerkontrolle unter Metformin: Eine randomisierte, doppelblinde, verumkontrollierte Nichtunterlegenheitsstudie über 52 Wochen

Deutsche Medizinische Wochenschrift

Volumn 138, Issue SUPPL. 1, 2013, Pages

  Nauck, M ^a   Del Prato, S ^b   Meier, J J ^c   Duran Garcia S ^d   Rohwedder, K ^e   Elze, M ^f   Parikh, S J ^e  

^a Diabeteszentrum   (Germany)

^b UNIVERSITY OF PISA   (Italy)

^c RUHR UNIVERSITY BOCHUM   (Germany)

^d HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^e ASTRAZENECA   (United Kingdom)

^f ClinResearch   (Germany)

Author keywords

dapagliflozin; SGLT 2 inhibitors; type 2 diabetes

Indexed keywords

DAPAGLIFLOZIN; GLIPIZIDE; GLUCOSE; HEMOGLOBIN A1C; METFORMIN;

ADD ON THERAPY; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GENITAL TRACT INFECTION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE; URINARY TRACT INFECTION; WEIGHT GAIN; WEIGHT REDUCTION;

AGED; BALANITIS; BLOOD GLUCOSE; BODY WEIGHT; CANDIDIASIS, VULVOVAGINAL; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GERMANY; GLIPIZIDE; GLUCOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; KAPLAN-MEIER ESTIMATE; MALE; METFORMIN; MIDDLE AGED; SODIUM-GLUCOSE TRANSPORTER 2; URINARY TRACT INFECTIONS;

EID: 84875287655     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0032-1305283     Document Type: Article

References (21)

1. International Diabetes Federation Global guideline for type 2 diabetes. [Online-Artikel]: 2005; http://www.idf.org/webdata/docs/IDF%20GGT2D.pdf (Stand: 30.08.2010)
2. Nathan D. M., Buse J. B., Davidson M. B. et al. American Diabetes Association; European Association for Study of Diabetes Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care: 2009; 32 193 203
3. Nathan D. M., Buse J. B., Davidson M. B. et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care: 2006; 29 1963 1972 (Pubitemid 44156663)
4. National Institute for Health and Clinical Excellence (NICE) Type 2 diabetes: national clinical guideline for management in primary and secondary care (update). [Online-Artikel] London NICE: 2008; http://www.nice.org.uk/ nicemedia/live/11983/40803/40803.pdf (Stand: 30.08.2010)
5. National Institute for Health and Clinical Excellence (NICE) Type 2 diabetes: newer agents. [Online-Artikel] London NICE: 2009; http://www.nice.org. uk/nicemedia/live/12165/44318/44318.pdf (Satnd: 30.08.2010)
6. Kahn S. E., Haffner S. M., Heise M. A. et al. ADOPT Study Group Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med: 2006; 355 2427 2443 (Pubitemid 44903747)
7. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet: 1998; 352 837 853
8. Yki-Järvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care: 2001; 24 758 767 (Pubitemid 32888861)
9. Meng W., Ellsworth B. A., Nirschl A. A. et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem: 2008; 51 1145 1149 (Pubitemid 351480378)
10. Bakris G. L., Fonseca V. A., Sharma K. et al. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int: 2009; 75 1272 1277
11. Komoroski B., Vachharajani N., Feng Y. et al. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther: 2009; 85 513 519
12. Ferrannini E., Ramos S. J., Salsali A. et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care: 2010; 33 2217 2224
13. Bailey C. J., Gross J. L., Pieters A. et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet: 2010; 375 2223 2233
14. Cockcroft D. W., Gault M. H. Prediction of creatinine clearance from serum creatinine. Nephron: 1976; 16 31 41
15. Zhang M., Tsiatis A. A., Davidian M. Improving efficiency of inferences in randomized clinical trials using auxiliary covariates. Biometrics: 2008; 64 707 715
16. Nauck M. A., Meininger G., Sheng D. et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab: 2007; 9 194 205 (Pubitemid 46206563)
17. Bloomgarden Z. T., Dodis R., Viscoli C. M. et al. Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis. Diabetes Care: 2006; 29 2137 2139 (Pubitemid 44871202)
18. Ferrannini E., Jimenez Ramos S., Salsali A. et al. Dapagliflozin mono-therapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial. Diabetes Care: 2010; 33 2217 2224
19. Shah B. R., Hux J. E. Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care: 2003; 26 510 513 (Pubitemid 36929083)
20. List J. F., Woo V., Morales E. et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care: 2009; 32 650 657
21. Wilding J.P.,Norwood P.,T'Joen C.,et al.A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: Applicability of a novel insulin-independent treatment Diabetes Care 2009 32 1656-1662.